Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry.

ABSTRACT:

Objective

We performed a real-world characterization of patients with rheumatoid arthritis (RA) who initiate a JAK inhibitor (JAKi) and switch to a subsequent therapy and examination of factors associated with the use of another JAKi/therapy with another mechanism of action (MoA).

Methods

This study included patients with RA in the US CorEvitas RA Registry who initiated a JAKi (August 16, 2019, to October 30, 2023), had prior exposure to at least one conventional synthetic disease-modifying antirheumatic drug (DMARD) and at least one biologic DMARD (bDMARD), and switched to another therapy within three months of JAKi discontinuation. Patients were classified as JAKi "cyclers" or "switchers" from JAKi to another MoA. Outcomes evaluated from JAKi initiation to cycle/switch inc

SUBMITTER: Baker JF 

PROVIDER: S-EPMC12572622 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature